Eli Lilly Opens Access to Obesity Drug Before Approval

Thousands of people struggling with obesity may soon get early access to a promising new treatment, thanks to a major policy shift from pharmaceutical giant Eli Lilly.

The company announced Monday it will accept applications from patients seeking early access to retatrutide, an obesity drug still awaiting FDA approval. Until now, only a single 79-year-old patient had been granted permission to use the medication outside of clinical trials.

The change came after doctors began requesting access for their patients and STAT News asked the company why those requests hadn't received responses. Lilly had previously shared little information about its special access program.

"For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval," a Lilly spokesperson said. The company confirmed it's actively reviewing requests from healthcare providers.

These special access programs, sometimes called compassionate use, allow seriously ill patients to try experimental treatments when they can't participate in clinical trials. Patients must meet strict medical criteria, and their doctors must formally request access.

The Ripple Effect

This policy shift could open doors for patients who have run out of options with existing obesity treatments. While retatrutide hasn't received FDA approval yet, it represents a new generation of weight loss medications showing promising results in clinical trials.

The announcement also signals a broader trend in pharmaceutical companies becoming more transparent about compassionate use programs. When patients and doctors don't know these programs exist, they can't advocate for access.

By making the application process public, Lilly is giving hope to patients whose health conditions make waiting for full FDA approval risky. Every person who gains access gets a chance at better health while the approval process continues.

This shift proves that patient advocacy and transparent journalism can create real change in healthcare access.